Name of Medicine - Medsafe
New Zealand Datasheet Name of Medicine Olanzapine-DRLA film coated tablets Olanzapine ODT-DRLA orodispersible tablets Presentation Olanzapine-DRLA 2.5 mg tablets are white, film coated, oval biconvex tablets
Download Name of Medicine - Medsafe
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Workshop 6 Modeling and Simulation to help …
www.agah.euModelling and simulation to help define MABEL and Starting dose in FIH studies B Laurijssens, BEL Pharm Consulting. Steven W Martin, Pharmacometrics Group, Dept Clinical Pharmacology,
DRUG NAME: Daunorubicin - BC Cancer
www.bccancer.bc.caDAUNOrubicin DRUG NAME: Daunorubicin SYNONYM(S): daunomycin, DNR, rubidomycin COMMON TRADE NAME(S): CERUBIDINE® CLASSIFICATION: Anthracycline topoisomerase inhibitor. Special pediatric considerations are noted when applicable, otherwise adult provisions apply.
DRUG NAME: Zoledronic acid - BC Cancer
www.bccancer.bc.caThe potential risk to humans is unknown; however in animal studies, zoledronic acid crossed the placental barrier, was taken up into the developing fetal skeleton, and caused external, visceral, and skeletal
COMMUNITY HERBAL MONOGRAPH ON …
www.ema.europa.eucommunity herbal monograph on hypericum perforatum l., herba (well-established medicinal use)
Anti-aging properties of resveratrol: review and …
www.grupotraversa.com.uyAnti-aging properties of resveratrol • R A Baxter 4 © 2008 Blackwell Publishing • Journal of Cosmetic Dermatology, 7 2–7 Resveratrol has also been shown to protect the brain
Journal of Pharmacological and Toxicological …
www.limef.combrain barrier (BBB), interact with central targets and precipitate an abuse liability potential. Thus, non-clinical testing should result in data derived from a robust, fundamentally sound set of studies
Partnering with Pfizer Worldwide R&D
www.pfizer.comPfizer is proud to offer you access to our world-class research scientists, our cutting-edge capabilities in medicine and vaccine design, our global network of
Related search queries
Starting dose, DRUG NAME: Daunorubicin, DRUG NAME: Zoledronic acid, Barrier, COMMUNITY HERBAL MONOGRAPH ON, Community herbal monograph on hypericum perforatum, Anti-aging properties of resveratrol: review, Anti-aging properties of resveratrol, Brain, Journal, Brain barrier, Partnering with Pfizer Worldwide, Pfizer